uploads/2018/10/NVCR-ana-reco-1.png

Gauging Analysts’ Views for NovoCure Stock

By

Updated

Analyst recommendations

Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.” The mean rating for NovoCure is 1.6 with a target price of $56.50. That implies an upside potential of 24.4% over its trading price of $45.42 on October 18.

In comparison, peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Intuitive Surgical (ISRG) have mean ratings of 1.8, 2.32, and 2.06, respectively. Their target prices are $78.65, $161.20, and $578.07, respectively.

Article continues below advertisement

Price performance

After a strong run from $20.25 on April 9 to a high of $53.70 on October 1, NovoCure stock has experienced selling pressure in October. It corrected to $43.87 on October 11. In the past week, it managed to recover to $46.50.

The enterprise value of NovoCure is $4.03 billion, and its enterprise-value-to-revenue ratio is 18.53x. Its price-to-sales and price-to-book ratios are 19.33x and 37.48x, respectively.

NovoCure’s current ratio, a metric of how effectively a company can meet its short-term obligations, is 6.40x. In comparison, the current ratios of Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Intuitive Surgical (ISRG) are 1.6x, 2.3x, and 6.0x, respectively.

Advertisement

More From Market Realist